RESUMEN
The interactions of GM-CSF with cells of lymphoid lineage are not well understood and their clinical use has been focused on the acceleration of hematopoietic recovery. However, several reports have shown that human GM-CSF can affect certain T lymphocyte in vitro cytotoxic functions. To assess whether recombinant human GM-CSF (rhGM-CSF) has a more broadly based activity in the immune system, we studied its in vivo effects on endogenously-generated killer function in patients undergoing ABMT for hematologic malignancies. Eleven patients received rhGM-CSF after ABMT: eight received rhGM-CSF as a 2-h infusion daily from days +3 to +17 and three received rhGM-CSF until reaching > 500 x 10(6)/l granulocytes. Eight patients not enrolled in the rhGM-CSF therapy protocol served as controls. Natural killer (NK) cell activity and activated killer (AK) cell activity were studied before conditioning, during rhGM-CSF therapy and after withdrawal of GM-CSF. rhGM-CSF therapy does not affect NK activity. Circulating lymphocytes with the ability to kill AK-sensitive targets appear spontaneously in control ABMT patients. AK activity was 1.6 +/- 0.8% before ABMT increasing to 9 +/- 2.5% and 14 +/- 2.1% at 2 and 3 weeks after ABMT, respectively (p = 0.002). In rhGM-CSF-treated patients this phenomenon also occurs. AK activity increased from 2.4 +/- 1.5% before ABMT to 33.6 +/- 8.1% during rhGM-CSF administration (p = 0.001) and 17.5 +/- 3.4% after withdrawal (p = 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)
Asunto(s)
Trasplante de Médula Ósea , Factor Estimulante de Colonias de Granulocitos y Macrófagos/uso terapéutico , Células Asesinas Activadas por Linfocinas/fisiología , Células Asesinas Naturales/fisiología , Leucemia/terapia , Subgrupos Linfocitarios/fisiología , Adolescente , Adulto , Niño , Preescolar , Terapia Combinada , Citotoxicidad Inmunológica/efectos de los fármacos , Femenino , Humanos , Células Asesinas Activadas por Linfocinas/efectos de los fármacos , Células Asesinas Naturales/efectos de los fármacos , Leucemia/patología , Leucemia/cirugía , Depleción Linfocítica , Subgrupos Linfocitarios/efectos de los fármacos , Masculino , Persona de Mediana EdadRESUMEN
Leukemic relapse is the major complication following autologous bone marrow transplantation (BMT) in acute myeloblastic leukemia (AML). Previously, we have shown that recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) infusion after autologous BMT has the ability to augment endogenous activated killer (AK) cell function which may play a role in the eradication of minimal residual disease. However, the clinical application of rhGM-CSF in patients with AML has been limited by its potential stimulatory effect on the malignant clone. Here we report the effect of rhGM-CSF 5 micrograms/kg/day infusion on AK cell function in 20 patients with AML undergoing autologous BMT. AK cell function was investigated before autologous BMT, during rhGM-CSF therapy and after withdrawal. In addition, its influence on the actuarial risk of relapse is analyzed and compared with a historical control group of 20 patients transplanted immediately before initiation of this study. rhGM-CSF significantly enhanced AK cell function. During rhGM-CSF treatment, median AK cell function rose from 1.8% before autologous BMT (range 0-8%) to 35% (range 3-80%) and remained increased after cessation of rhGM-CSF (median 20%; range 0-36%; P < 0.001). After a median follow-up of 24 months, the actuarial risk of relapse is 37.4% in rhGM-CSF-treated patients compared with 49.5% in controls (P = 0.05). Interestingly, none of the 7 patients with an AK cell activity > or = 20% in the first 2-5 weeks after autologous BMT have relapsed compared with 6 of 9 patients with an AK cell activity < 20% (P < 0.02).(ABSTRACT TRUNCATED AT 250 WORDS)
Asunto(s)
Trasplante de Médula Ósea/inmunología , Factor Estimulante de Colonias de Granulocitos y Macrófagos/administración & dosificación , Células Asesinas Naturales/inmunología , Leucemia Mieloide Aguda/terapia , Adolescente , Adulto , Niño , Preescolar , Femenino , Humanos , Leucemia Mieloide Aguda/inmunología , Activación de Linfocitos , Masculino , Persona de Mediana Edad , Proteínas Recombinantes/administración & dosificación , Recurrencia , Trasplante AutólogoRESUMEN
Theoretical considerations and preliminary results of clinical trials support the earlier use of autologous bone marrow transplantation (ABMT) in poor prognosis non-Hodgkin's lymphoma (NHL). A prognostic analysis of 50 patients with intermediate or high grade NHL younger than 60 years, who achieved at least one complete remission and were not treated with BMT, was performed. Patients with bulky tumor at diagnosis and/or serum LDH greater than or equal to 600 U/l do poorly with conventional chemotherapy. Twelve patients with these high-risk initial characteristics in first complete remission (CR) and six patients in second or third CR were treated with cyclophosphamide (60 mg/kg x 2) and total body irradiation (1000-1200 cGy) followed by ABMT. Overall disease-free survival was 65% at a median follow-up of 35 months. No differences were found between the first and later CR patients. The rate of toxic death was 11%. Disease-free survival after first CR was better for 1st CR ABMT patients than for a historical chemotherapy control group with similar poor prognosis features (p = 0.008). These results support the use of ABMT in selected, high-risk NHL patients in first CR.
Asunto(s)
Trasplante de Médula Ósea , Linfoma no Hodgkin/cirugía , Adolescente , Adulto , Antineoplásicos/uso terapéutico , Trasplante de Médula Ósea/efectos adversos , Trasplante de Médula Ósea/mortalidad , Niño , Femenino , Humanos , Linfoma no Hodgkin/tratamiento farmacológico , Masculino , Persona de Mediana Edad , Pronóstico , Trasplante AutólogoRESUMEN
A 39 year old patient diagnosed of severe aplastic anemia and treated with allogenic bone marrow transplantation and who presented chronic eosinophilic pneumonia eight months after the transplant is presented. The patient had no previous history of asthma or atopy. Conditioning was performed with cyclophosphamide and total body irradiation. Prophylaxis of the graft versus host disease was carried out with cyclosporin and short course of methotrexate. At day 30 mild graft versus host disease appeared which spontaneously resolved. A progressive increase in the number of eosinophils was observed from day +40 reaching 1.05 x 10(9)/l at day +180 coinciding with suspension of the cyclosporine. The patient remained asymptomatic with no evidence of chronic graft versus host disease. At 8 months following allogenic transplantation the patient developed three episodes of fever, cough, moderate dyspnea and pulmonary infiltrates. Respiratory tests showed a restrictive pattern. Bronchoalveolar lavage contained 20% of eosinophils. Upon lung biopsy alveolar infiltration by eosinophils, lymphocytes and mononuclear cells was observed. Diagnosis of chronic eosinophilic pneumonia was made with initiation of steroid treatment. A drastic response was observed. The patient remained asymptomatic without recurrence and without evidence of chronic graft versus host disease. This picture may have been caused by the donor eosinophils given that retrospective evaluation demonstrated a persistent moderate eosinophilia in the donor.
Asunto(s)
Trasplante de Médula Ósea/efectos adversos , Eosinofilia Pulmonar/etiología , Adulto , Enfermedad Crónica , Humanos , Masculino , Eosinofilia Pulmonar/patologíaRESUMEN
Relapsing polychondritis and Ulcerative Colitis is an uncommon association that has been described only ten times in medical literature. We report a new case of this association in which it was necessary to treat with azathriopine to stop disease progression. Relapsing Polichondritis is a disorder to be considered in patients with Ulcerative Colitis and inflammation of the cartilagenous structures.
Asunto(s)
Colitis Ulcerosa/complicaciones , Policondritis Recurrente/complicaciones , Adulto , Humanos , MasculinoRESUMEN
A 56-year old woman with non-secretory multiple myeloma presented with involvement of the base of brain and meningeal infiltration. Initial involvement of central nervous system is very rare in multiple myeloma, no such pathology being reported in non-secretory myeloma thus far.
Asunto(s)
Neoplasias Meníngeas/patología , Mieloma Múltiple/patología , Neoplasias Craneales/patología , Hueso Esfenoides , Hueso Temporal , Médula Ósea/patología , Resultado Fatal , Femenino , Humanos , Neoplasias Meníngeas/líquido cefalorraquídeo , Persona de Mediana Edad , Mieloma Múltiple/líquido cefalorraquídeo , Proteínas de Mieloma/análisis , Células Plasmáticas/química , Células Plasmáticas/patología , Neoplasias Craneales/líquido cefalorraquídeoRESUMEN
Research of the alcohol action mechanism on the SNC in acute alcoholic intoxication (AAI) has been dealt in various ways. On one side the alcohol action--apparently most unspecific--on cellular membranes has been studied. Other authors, instead, have studied more specific alcohol effects on three types of neurotransmitters: opioid peptides, GABA and catecholamines. The effect of alcohol on cellular membranes seems to be beyond any doubt. Alcohol action on specific neurotransmitters is the object of controversy, especially in the case of endogenous opioids. There are data which strongly support the participation of the GABA receptors in the AAI. Modifications produced in the cellular membrane by alcohol action can modify the structure of the function of the membrane receptors. On the other hand, distinct receptors may be localized in the same neuron, while the existence of interactions between different neurotransmitters is well known. Therefore, the various hypotheses previously stated are not mutually exclusive.
Asunto(s)
Intoxicación Alcohólica/fisiopatología , Encéfalo/efectos de los fármacos , Etanol/farmacología , Neuronas/efectos de los fármacos , Receptores de GABA-A/efectos de los fármacos , Receptores Opioides/efectos de los fármacos , Animales , Azidas/farmacología , Benzodiazepinas/farmacología , Membrana Celular/efectos de los fármacos , Humanos , Naloxona/farmacología , Neuronas/ultraestructuraRESUMEN
Eleven cases of leptospirosis diagnosed from 1988 to 1994 were retrospectively reviewed. The mean age of the patients was 52 years. Epidemiologic factors were found in 10 patients. Hepatorenal involvement was observed in 7 cases (64%), cardiac involvement in 3 (27%), bleeding episodes in 5 (45%) and central nervous system involvement in one case (9%). The Leptospira serogroups identified were: Icterohaemorrhage in 6 cases, Pomona in 1, Sejroe in and could not be determined in 3. One patient died because of multiorgan failure. The epidemiologic, clinical, analytical and therapeutic aspects are discussed.
Asunto(s)
Leptospirosis/epidemiología , Adulto , Cardiomiopatías/etiología , Hematuria/etiología , Humanos , Ictericia/etiología , Leptospira/clasificación , Leptospira/aislamiento & purificación , Leptospirosis/complicaciones , Leptospirosis/microbiología , Leptospirosis/patología , Masculino , Persona de Mediana Edad , Insuficiencia Multiorgánica/etiología , Enfermedades Profesionales/epidemiología , Enfermedades Profesionales/microbiología , Estudios Retrospectivos , España/epidemiologíaAsunto(s)
Leucemia Neutrofílica Crónica , Aberraciones Cromosómicas , Células Clonales/patología , Progresión de la Enfermedad , Humanos , Leucemia Neutrofílica Crónica/genética , Leucemia Neutrofílica Crónica/patología , Mieloma Múltiple/patología , Síndromes Mielodisplásicos/patología , Neoplasias Primarias Múltiples/patología , Células Madre Neoplásicas/patología , Neutrófilos/fisiología , Paraproteinemias/patologíaRESUMEN
No disponible